Rising Biosciences, Inc. To
Offer Cannophen to Patients in Ohio, Florida; Launches Initiatives
for National Distribution of Scar Peptide Serum
Sandusky, OH
-- February 20, 2018 -- InvestorsHub
NewsWire -- Rising India, Inc.'s (OTC:
RSII) --Rising Biosciences, Inc., a
research and development company focusing on oral and topical
pharmaceuticals with strict standards set forward by the
pharmaceutical compounding industry, is pleased
to announce that it will partner with PAO Group's (OTC:
PAOG) Alternative Medicine
Centers of America to offer a
free trial of Cannophen to patients
in the state of Ohio. Anyone with a valid Ohio recommendation can
apply for the trial at our Ohio clinics; this will be done on
a patient to
patient basis.
Cannophen is an oral
capsule with laboratory controlled metered dosing that can be
blended in exacting ratios of THC, CBD and strain specific
terpenes.
It is easily digestible and fast acting and designed for patients
that do not want to smoke/vape
or use
off-tasting tinctures.
"This is a
monumental event for our company and one that means quite a bit to
me personally," states COO Arthur Hall. " I have been using
Cannophen since its earliest
development stages in hopes to explore and discover its beneficial
properties. Initially I was taking for symptoms of Parkinson's and
was astounded by overall results: I had also been battling cancer
for some time and through surgery, limited chemotherapy and the use
of Cannophen I am now cancer free. My
physicians are okay with the continued use of
Cannophen for maintenance.
We are grateful
to be sharing this with other patients beginning with the program
in Ohio I also will be meeting with a Producer/Processor in
California next week that has demonstrated serious interest in
licensing and distributing Cannophen
and other
Rising Biosciences products".
Mounting
evidence shows 'cannabinoids' in marijuana slow cancer growth,
inhibit formation of new blood cells that feed a tumor, and help
manage pain, fatigue, nausea, and other
side effects.
According to The National
Cancer Institute,
Studies in
mice and rats have shown that cannabinoids may inhibit tumor growth
by causing cell death, blocking cell growth, and blocking the
development of blood vessels needed by tumors to grow.
Laboratory and animal
studies have shown that
cannabinoids may be able to kill cancer cells while protecting
normal cells. One notable study of delta-9-THC
in hepatocellular
carcinoma (liver cancer) cells showed
that it damaged or killed the cancer cells. The same study of
delta-9-THC in mouse
models of liver cancer showed that
it had antitumor effects.
Delta-9-THC has been shown to cause these effects by acting on
molecules that may also be found in non-small cell lung
cancer cells
and breast
cancer cells.
As well,
Rising Biosciences is nearing completion on its FDA testing of
the TSW (This Sh**
Works) pain cream
products and is currently working with a company for national
distribution of its Scar Peptide Serum.
Rising Biosciences Scar Peptide Serum
The
following image depicts a patient who used the serum post-surgery
to diminish scars, to astounding results: 
Before and after surgery using Rising Bioscience's Scar
Peptide Serum to diminish scars
"Rising Biosciences Inc. along
with PAO Group Inc. helping reduce the grip of opioids on America
through the responsible use of cannabis"
$RSII
on Twitter for LIVE company updates! www.twitter.com/risingindiausa
Forward-Looking
Statements: Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933 and Rule 3b-6 under the Securities
Exchange Act of 1934, and are subject to the safe harbor created by
those rules. All statements, other than statements of fact,
included in this release, including, without limitation, statements
regarding potential future plans and objectives of the company, are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The Company undertakes no duty to revise or update any
forward- looking statements to reflect events or circumstances
after the date of this release.
CONTACT
INFO: For
Investor Inquiries:IR@risingbiosciences.com
